Biology Reference
In-Depth Information
159. Muller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ. The immune system and
schizophrenia: an integrative view. Ann NY Acad Sci 2000;917:456-67.
160. Schwarz MJ, Muller N, Riedel M, Ackenheil M. The Th2-hypothesis of schizophrenia:
a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med
Hypotheses 2001;56:483-86.
161. Gilmore JH, Jarskog LF, Vadlamundi S, Lauder JM. Prenatal infection and risk for
schizophrenia: IL-1, IL-6 and TNF- inhibit cortical neuron dendritic development.
Neuropsychopharmacology 2004;29:1221-29.
162. Tohmi M, Tsuda N, Watanabe Y, Kakita A, Nawa H. Perinatal inflammatory cytokine
challenge results in distinct neurobehavioural alterations in rats: implication in psychiat-
ric disorders of developmental origin. Neurosci Res 2004;50:67-75.
163. Gallien M, Schnetzler JP, Morin J. Antinuclear antibodies and lupus cells in 600 hospi-
talized phenothiazine treated patients. Ann Med Psychol Med 1977;1:237-48.
164. Zarrabi MH, Zucker S, Miller F, Derman RM, Romano GS, Hartnett JA, et al.
Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern
Med 1979;91:194-99.
165. Bertini S, Bianchi M, Mengozzi M, Ghezzi P. Protective effect of chlorpromazine against
the lethality of inteleukin-1 in adrenalectomized or actinomycin D-sensitized mice.
Biochem Biophys Res Commun 1989;165:942-47.
166. Gadina M, Bertini R, Mengozzi M, Zandalasini M, Mantovani A, Ghezzi P. Protective
effects of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-
sensitive and glucocorticoid-resistant models of endotoxin shock. J Exp Med 1991;173:
1305-10.
167. Boukhris W, Kouassi E, Revillard JP. Differential effect of mixed D
1
/D
2
and selective D
2
dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin
production
in vitro
. Immunopharmacol Immunotoxicol 1988;10:501-12.
168. Schlenning MI, Duggan A, Reem GH. Inhibition by chlorpromazine of lymphokine-spe-
cific mRNA expression in human thymocytes. Eur J Immunol 1989;19:1491-96.
169. Schlenning M, Brumme V, Wilmanns W. Inhibition of cyclosporin A/FK506 resis-
tant lymphokine-induced T-cell activation by phenothiazine derivatives. Naunyn
Schmiedebergs Arch Pharmacol 1994;350:100-3.
170. Rapaport MH, McAllister CG, Pickar D, Nelson DM, Paul SM. Elevated levels of solu-
ble interleukin-2 receptors in schizophrenia. Arch Gen Psychiatry 1989;46:292.
171. Rapaport MH, Torrey EF, McAllister CG, Nelson DM, Pickar D, Paul SM. Increased
serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. Eur Arch
Psychiatry Clin Neurosci 1993;243:7-10.
172. Rapaport MH, McAllister CG, Kim YS, Han JH, Pickar D, Nelson DM, et al. Increased
soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients. Biol
Psychiatry 1994;35:767-71.
173. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: com-
parison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994;89:346-51.
174. Monteleone P, Fabrazzo M, Tortorella A, Maj M. Plasma levels of interleukin-6 and
tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment.
Psychiatry Res 1997;71:11-17.
175. Sperner-Unterweger B, Gaggl S, Fleischhacker WW, Barnas C, Herold M, Geissler D. Effects
of clozapine on hematopoiesis and the cytokine system. Biol Psychiatry 1993;34:536-43.
176. Muller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Moller HJ, et al.
Cox-2 inhibition as a treatment approach to schizophrenia: immunological considerations
and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci
2004;254:14-22.
